This study tests how well a drug called amivantamab-SC works for patients with a type of lung cancer called non-small cell lung cancer (NSCLC) that has extra copies of the MET gene. The MET gene is part of your DNA, and when it copies too much, it can make cancer grow or spread. The drug aims to reduce these extra copies and help stop the cancer from getting worse. In this study, patients receive the drug as a shot under the skin on certain days of the treatment cycle. They will have cycles of treatment every 28 days as long as the cancer doesn’t get worse or they don't experience bad side effects. Patients will also have regular scans like CT or MRI and give blood samples. The study lasts up to 3 years, including follow-ups.

• Study Duration: Each treatment cycle is 28 days; follow-up for up to 3 years.
• Visits Needed: Regular check-ups and scans during the trial.
• Potential Risks: Side effects of the drug and regular blood tests.